AD 2051
Alternative Names: AD-2051Latest Information Update: 28 Sep 2023
At a glance
- Originator Addpharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Unspecified(Combination therapy, In volunteers) in South Korea
- 28 Sep 2023 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in South Korea
- 15 Dec 2020 Addpharma completes enrolment in the phase I trial for Unspecified in South Korea (KCT0005484)